Entrectinib-d4
Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib. Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice[1][2][3].
Product Specifications
Product Name Alternative
NMS-E628-d4; RXDX-101-d4
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; Autophagy; Isotope-Labeled Compounds; ROS Kinase; Trk Receptor
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Neuronal Signaling; Others; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
O=C(NC1=NNC2=C1C=C(CC3=CC(F)=CC(F)=C3)C=C2)C4=C(NC5C([2H])([2H])COCC5([2H])[2H])C=C(N6CCN(C)CC6)C=C4
Molecular Formula
C31H30D4F2N6O2
Molecular Weight
564.66
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
